Why it jumped over 40% today

  • Ekso Bionics Holdings Inc (NASDAQ:EKSO) stock price rose more than 40% in intraday trading today. That is why.

Ekso Bionics Holdings Inc (NASDAQ:EKSO) stock price rose more than 40% in intraday trading today. Investors are reacting positively to Ekso Bionics Holdings’ announcement that it has received 510(k) clearance from the United States Food and Drug Administration (FDA) to market its EksoNR robotic exoskeleton for multiple sclerosis patients in plates (SEP). And EksoNR is the first exoskeleton device to receive FDA clearance for use in rehabilitation in MS patients, an indication that greatly expands the use of the device to a broader group of patients.

EksoNR is known as the most clinically used next-generation robotic exoskeleton device on the market. It was previously cleared by the FDA for stroke and spinal cord injury rehabilitation in 2016 and acquired brain injury (ABI) in 2020. And the device was the first of its kind to receive an indication for ‘AVC, is the only exoskeleton with an ABI indication, and is now the first to receive an indication for MS.

MS is known as a neurodegenerative disease of the central nervous system that disrupts the flow of information within the brain and between the brain and the body. And in people between the ages of 20 and 40, MS symptoms can include neurological deficits, ranging from visual impairment and fatigue to numbness and difficulty walking.

In addition to its FDA clearances, EksoNR is CE marked and available in Europe. Used by more than 375 rehabilitation centers worldwide, Ekso devices have helped patients take nearly 200 million steps, while supporting patients’ hopes for mobility and independence.

KEY QUOTE:

“As a leader in wearable robotic solutions for medical rehabilitation, which are marketed upstream, we are committed to maximizing patient access to our technology. With indications for use now expanded to include MS, EksoNR has the potential to help many more patients and improve patient mobility. We are thrilled to see the device benefiting MS patients, providing much-needed rehabilitation solutions, just as it has done for patients suffering from stroke, spinal cord injury and brain injury. acquired.

— Steven Sherman, President and CEO of Ekso Bionics

Disclaimer: This content is intended for informational purposes. Before making any investment, you should do your own analysis.

Eleanor C. William